WAM
SABS icon

Warberg Asset Management’s SAB Biotherapeutics SABS Stock Holding History

Warberg Asset Management’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-17,766
Closed -$78.2K – 262
2023
Q1 		$78.2K Sell
17,766
-19,271
-52% -$122K 0.02% 133
2022
Q4 		$219K Buy
+37,037
New +$339K 0.03% 102

Other funds holding SABS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FPB
First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return
V
Veritable Wilmington, Delaware $6.46B AUM 17.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
IFAM
Institutional & Family Asset Management Fort Collins, Colorado $654M AUM 12.29% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

Warberg Asset Management's SABS Position: Q2 2023 in Review

Warberg Asset Management sold out of SAB Biotherapeutics (SABS) in Q2 2023, closing a stake of 17,766 shares — an estimated $78.2K sold.

Warberg Asset Management first reported a position in SABS in Q4 2022 and held it in 2 quarters. The position peaked at $219K in Q4 2022. 38 funds tracked by Wall St. Rank hold SABS as of Q2 2023.

  • Warberg Asset Management reported no remaining SAB Biotherapeutics position as of Q2 2023 after selling out during the quarter.
  • Warberg Asset Management sold 17,766 SAB Biotherapeutics shares in Q2 2023, an estimated $78.2K.
  • Warberg Asset Management first reported a position in SAB Biotherapeutics in Q4 2022 and held it in 2 quarters.
  • Warberg Asset Management's SAB Biotherapeutics position peaked at $219K in Q4 2022.
  • 38 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2023.

Based on Warberg Asset Management's 13F filing for Q2 2023, filed 9 Aug 2023.